23 November 2017
News and Views
Links and Services
A study published in the latest New England Journal of Medicine evaluates the use of everolimus for advanced pancreatic neuroendocrine tumors.
Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activi
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors